Comparing the Latest Stool- Based and Blood-Based Colorectal Cancer Screening Tests

Author(s):

Key Takeaways

Stool DNA tests, like Cologuard, demonstrate high sensitivity (92%) and specificity (87%) for colorectal cancer detection, analyzing DNA markers and hemoglobin in stool samples.
Blood-based tests, such as Epi proColon, detect circulating tumor DNA or methylated DNA markers, offering a less invasive alternative to colonoscopy.
Blood-based tests generally have lower sensitivity compared to stool DNA tests but provide a complementary screening option for patients.

Vivek Kaul, MD, discusses the sensitivity and accuracy of the stool DNA test, providing relevant data, while also describing the role of blood-based tests in colorectal cancer screening and how they complement or differ from stool-based tests.

EP: 1.Importance of Colorectal Cancer Screening and Guidelines

EP: 2.Options for CRC Screening and Need for Patient- Centered Decision-Making

EP: 3.Overview of Stool DNA Test for CRC

Now Viewing

EP: 4.Comparing the Latest Stool- Based and Blood-Based Colorectal Cancer Screening Tests

What do we know about the sensitivity and accuracy of the stool DNA test, including any relevant data?
Can you describe the role of blood-based tests in colorectal cancer screening and how they complement or differ from stool-based tests?